# OnCo record gedatolisib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/gedatolisib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "gedatolisib" ;
  schema:name "Gedatolisib"@en ;
  schema:description "An intravenous drug that blocks the whole PI3K/mTOR pathway, approved in July 2026 for hormone-positive breast cancer."@en ;
  schema:url <https://onco.cc/drugs/gedatolisib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Gedatolisib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule pan-PI3K/mTOR inhibitor" ;
  schema:alternateName "Revtorpyk" ;
  onco:approval "US 2026: HR+/HER2- advanced breast cancer after CDK4/6 inhibitor (July 2026)" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/akt/> ;
  onco:companies <https://onco.cc/companies/celcuity/> ;
  onco:trials <https://onco.cc/trials/nct06190899/>, <https://onco.cc/trials/nct05501886/>, <https://onco.cc/trials/nct06757634/> .